Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...
Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...
Fintel on MSN5d
Wells Fargo Upgrades Regulus Therapeutics (RGLS)
Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal ...
Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)
Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Regulus (RGLS – Research Report) today and set a price target of $7.00. The ...
American Association of Individual Investors5d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 13.67%
Regulus Therapeutics Inc.’s RGLS share price has surged by 13.67%, which has investors questioning if this is right time to ...
Wells Fargo & Company Upgrades Regulus Therapeutics (NASDAQ:RGLS) to Overweight
Wells Fargo & Company upgraded shares of Regulus Therapeutics (NASDAQ:RGLS – Free Report) from an equal weight rating to an ...
Seeking Alpha5d
Regulus jumps after data from early-stage trial for kidney disease therapy (update)
Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...
Investing.com Australia5d
Regulus shares surge on Wells Fargo upgrade, clinical update
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo (NYSE: WFC) ...